CURRICULUM VITAE

Edwin D. Dunteman, M.D., M.S.

Personal Information:

Home: *** ******** **.

Dardenne Prairie, MO 63368 Cell Phone: 314-***-****

Born March 3, 1957

ac0yf0@r.postjobfree.com

Education:

May 1979 B.A. in Physiology

Southern Illinois University; Carbondale, IL

August 1984 M.S. in Physiology

Southern Illinois University, Carbondale, IL;

Thesis: The Regional Contractile and Hemodynamic Responses to Thirty Minutes of Coronary Occlusion and Thirty Minutes of Reperfusion in the Dog.

June 1989 M.D. Degree

University of Illinois at Chicago, Chicago, IL

Postgraduate Training:

1989 - 1990 Intern, Transitional/Internal Medicine

St. John’s Mercy Medical Center, St. Louis, MO

1990 - 1993 Resident in Anesthesiology

Washington University School of Medicine, St. Louis, MO

1993 - 1994 Fellow in Pain Management

Washington University School of Medicine, St. Louis, MO

Nov. 1993 Pediatric Pain Management (one month rotation) at Harvard Medical School, Boston Children’s Hospital

Board Certification and Licensure:

Licensure in MO #MD R8N65

Anesthesiology - Board Certified

Pain Management - Board Certified

Professional and Academic Appointments:

03/07/17-Present: The Health Centers

2621 Raymond Dr. St. Charles, MO, 63301

Pain Management Physician

1/02/17- Present: Pain Relief Associates

2682 Babble Creek Lane, O’Fallon, MO, 63368

Pain Management Physician

10/01/16- 12/01/16: Elpis Pain Management Center

4122 Keaton Crossing Blvd Ste 102

O’Fallon, MO 63368

6/08/15-10/14/16 : Laser Spine Institute of St. Louis.

450 North New Ballas Rd. St Louis, MO 63141

Attending- Diagnostics. Active Thru 7/15/16

9/22/14-5/18/15 Comprehensive Pain Specialists- St. Louis

555 N. New Ballas, #165, St. Louis, MO 63141

Attending, after purchase of A&A Pain

7/00-9/22/2014 A & A Pain Institute of St. Louis

St. Louis, MO

Director and President

7/98-7/2000 Director of Pain Management

Missouri Bone & Joint Center

St. Louis, MO

9/97 -7/1998 Executive Director

SLUCare Pain Management Network

St. Louis University School of Medicine

St. Louis, MO

9/97 - 7/1998 Assistant Professor and Attending

Pain Management Center/Department of Anesthesiology

Saint Louis University School of Medicine

7/95 - 9/1997 Director Pain Management Center

Barnes Jewish West County Hospital/Washington University

7/94 - 9/1997 Attending Pain Management Center at Washington University School of Medicine

-7/93 – 6/94 – Fellow in Pain Management

-7/94 – 5/96 – Instructor Department of Anesthesiology

-6/96 – 9/97 – Assistant Professor Department of Anesthesiology

-

2/91- 6/1994 St. John’s Mercy Medical Center, Dept of Emergency Medicine

Creve Coeur, MO.

Emergency Department Physician, Part-time

Professional and Academic Appointments Cont,:

6/88 - 9/1988 Research Associate

Depts. Of Neonatology and Pediatric Surgery

University of Illinois College of Medicine

Chicago, IL

6/86 - 6/1987 Research Associate

Dept. Of Neonatology

University of Illinois College of Medicine

Chicago, IL

9/84 - 7/1985 Researcher I

Southern Illinois University (S.I.U.) College of Medicine

Carbondale, IL

8/82 - 6/1984 Teaching Assistant

Dept. Of Physiology

Southern Illinois University (S.I.U.)

Carbondale, IL

8/81 - 8/1983 Research Assistant

Southern Illinois University (S.I.U.), College of Medicine

Carbondale, IL

Bibliography:

Published Papers and Accepted Manuscripts:

1.Myers H, Schalk K, Sargent W, Peters J, Dunteman E, Hadlock J, Beard J. Cerebral blood flow and CNS oxygen consumption during chronic ethanol in conscious dogs. Physiologist 1982; 25:324.

2.Dunteman E, Peter J, Schalk K, Isaacson T, and Myers H. Verapamil provides rapid recovery of regional myocardial function following coronary reperfusion. Fed Proc 1985; 44:830.

3.Dunteman E, Despotis G. A simple method of MDI administration in the intubated patient. Anesth. Analg. 1992; 75:304-5.

4.Dunteman E, Hirshberg G. An alternative precordial stethoscope. Anesthesiology 1993; 78:1118-1119.

5.Dunteman E, Swarm R. Atypical Facial Neuralgia. Anesth. Analg. 1995; 80:188-190.

6.Dunteman 6.E, Turner S, Swarm R. Pseudo-spinal Headache. Regional Anesthesia 1996; 21(4):358-60.

Published Papers and Accepted Manuscripts Continued:

7.Dunteman E, Karanikolas M, Filos K. Transnasal Butorphanol for the treatment of opioid induced pruritus, unresponsive to antihistamines. Journal of Pain and Symptom Management 1996; 12(4):255-60.

Also Abstracted in: Journal of American Medical Association 1997; 227(20):1578

Abstracted and Reviewed: Tinker JH, Abram SE, et al (editors). The Yearbook of Anesthesiology & Pain Management. Mosby, St. Louis, 1997; 215-216.

8.Dunteman E, Alternative Medicine in my Patients? Probably! Invited Guest Editorial. St. Louis Metropolitan Medicine 1998: 20(10) 6- 7.

9.Dunteman E, Alternative Medicine Use in our Patients. Invited Focus Article. St. Louis Metropolitan Medicine 1998; 20(10) 14-15.

10.Dunteman E, When Should an Algologist be Consulted? Invited Focus Article, St. Louis Metropolitan Medicine 1999; 21(1) 18-20.

11.Dunteman E, Peripheral Nerve Stimulation for Unremitting Ophthalmic Postherpetic Neuralgia. Neuromodulation 2002; 5(1) 32-37.

12.Herndon C., Kalauokalani D, Cunningham A., Jackson K, Dunteman E: Anticipating and treating opioid associated adverse effects. Expert Opinion on Drug Safety. 2003; 2(3):305-319

13.Herndon CM., Kalauokalani DK., Dunteman, E: Pain Research Update: Overview of Pain Management Research for the Practicing Clinician: American Journal of Pain Management: 2003;13:152-156

14.Dunteman E.: Anticonvulsant Therapy and Neuropathic Pain: A Novel Treatment Approach: Journal Club-Neurology. Invited Editorial 2003:8(2);2-3.

15.Dunteman E.: A Brief Review of Mechanisms and Pharmacologic Treatment Approaches for Chronic Neuropathic Pain: Canadian Journal of Anesthesia, Invited Review Article:2004:51(6);R1-R4

16.Dunteman E.: Fibromyalgia and Myofascial Pain Syndromes: A practical Approach to the Differential Diagnosis and Treatment of Fibromyalgia and Myofascial Pain Syndromes: Practical Pain Management: 2004:4(4):26-29.

17. Dunteman, E.: Levetiracetam in Neoplastic Plexopathies: Case Series and Commentaries: Journal of Pain and Palliative Care Pharmacotherapy. 2005:19(1) 29-37

Published Papers and Accepted Manuscripts, Continued:

18.Dunteman, E.: Myofascial Elements of Low Back Pain. Practical Pain Management. 2005:5(2) 29-32.

19.Dunteman, E.: Targeted Peripheral Analgesics in Chronic Pain Syndromes. Practical Pain Management. 2005:5(5) 14-25.

20.Irving G, Backonja M, Dunteman E, Blonsky R, et al. : A Multicenter, Randomized, Double-Blind, Controlled Study of NGX-4010, A High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia. Pain Medicine. 2011: 12(1) 99-109.

21.Webster LR, Nunez M, Tark MD, Dunteman ED, Lu B, Tobias JK, Vanhove GF: Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia. BMC Anesthesiology. 2011:11(1) 25

22.Markley HG, Dunteman ED, Sweeney Michael: Real-World Experience with Once Daily Gabapentin for the treatment of Postherpetic Neuralgia (PHN). Clin J Pain 2015;31:58-65

Monograph & Book Chapters Instruction Videos:

Dunteman E, Botox use in Chronic Low Back Pain – in. Sutherland L. Editor. Emerging Treatment Options for Myofascial Pain Syndromes. Monograph/Video. Discovery International, Chicago, IL. 1999

Dunteman E, Lang A., Shim J. :Exploring the Evolving Role of Botulinum Neurotoxin in Pain Management- in Staats P. Johns Hopkins University School of Medicine: Editor. Practice with the Experts: Treatment Monograph/ Video: Alpha Medica, Terrytown New York. 12/2002.

Dunteman E: Anticonvulsant Treatment and Immune Responses to Pain; in Irving G, Goli V, and Dunteman E : An Expert Review of Clinical Challenges in Psychiatry and Neurology: CME Accredited Roundtable Monograph: CNS Spectrums/MLB New York, New York 09/2004.

Abstracts:

1.Fogel ST, Norris, MK, Monsey C, Dunteman E, Transnasal Butorphanol for Neuraxial Opioid Induced Pruritis in the Parturient Anesthesia & Analgesia 1998:86:5366.

2. Kolodziejczyk, R, Dunteman E. Botox injections for chronic low back pain

syndrome treatment: Midwest Anesthesia Residents Conference: Minneapolis MN 3/1998.

3. Dunteman E: Levetiracetam adjunctive analgesia in neoplastic

Plexopathies: American Pain Society National Conference: Chicago, IL 3/2003.

4. Dunteman E: Chronic Low Back Pain Treatment with Botulinum Toxin Type-A

American Pain Society National Conference: Chicago, IL 3/2003

5. Dunteman E :Botulinum Neurotoxin Type A (BoNT-A) for relief of Chronic Low

Back Pain. American Society of Regional Anesthesia and Pain National Conference: San Diego, CA 10/2003

6. Dunteman E. Levetiracetam administered by rectal route is effective in treating neuropathic pain. American and Canadian Pain Societies National Conference : Vancouver B.C. 3/2004

7.Dunteman E. Rectally administered Levetiracetam is effective in treating complex pain syndromes. 7th International Conference on the Mechanisms and Treatment of Neuropathic Pain. Southampton, Bermuda 11/2004

8.Backonja MM, Dunteman E, Irving GA, Blonsky ER, Vanhove GF, Lu S-P, Tobias J: One 60-minute application of a high-concentration capsaicin patch (NGX-4019) significantly reduced pain for up to 3 months in patients postherpetic neuralgia: results from a randomized, double-blind, controlled Phase 3 study. American Academy of Neurology, Chicago, IL: April 2008 Currently in press.

9.Backonja MM, Dunteman E, Irving GA, Blonsky ER, Vanhove GF, Lu S-P, Tobias J:A Single One-Hour Application of NGX-4010 (Capsaicin Dermal Patch) Significantly Reduced Pain for up to 12 weeks: Results of a second randomized, double-blind, 12-week controlled study in Postherpetic Neuralgia patients. American Academy of Pain Management, Orlando, FL.2/ 2008.

10.Backonja MM, Dunteman E, Irving GA, Blonsky ER, Vanhove GF, Lu S-P, Tobias J:A Single One-Hour Application of NGX-4010 in Post Herpetic Neuralgia. American Academy of Pain Management. Nashville TN 9/08 In Press

11.Sweeney M, Dunteman E, Markley H.: Safety and efficacy of gastroretentive gabapentin in real-world clinical practice for treatment of elderly patients with postherpetic neuralgia (PHN) The Journal of Pain 14(4), S61, April 2013

Abstracts Continued

12.Dunteman, ED, McFann A, Tavel EM, Sweeney M: Safety and Efficacy of Gastroretentive Gabapentin in Real-World Clinical Practice for Patients with Postherpetic Neuralgia. American Academy of Pain Medicine. Fort Lauderdale, Fl 4/2013

13.Smith W, Brown BS, Dunteman ED, Sweeney M..:Phaze 4 Study of Gastroretentive Gabapentin for PHN. American Academy of Pain Management Annual Clinical Meeting. Orlando, Fl. 9/2013

14.Dunteman E, Wallace M, Adler C, Argoff C, et al: Effect of gabapentin enacarbil (GEn) on adverse events (AEs) by age group in a randomized, placebo-controlled trial of patients with postherpetic neuralgia (PHN). The Journal of Pain 16(4), S396, April 2015

Past Research Support:

1. Primary Investigator, Double-Blind Randomized Placebo-Controlled Parallel Groups Multi-Center Trial to Determine the Efficacy and Safety of Neurontin (gabapentin) in Subjects with Peripheral Neuropathy (postherpetic neuralgia). Protocol 945 - 211. 1996 – 1997

Rowbotham M, Harden N, et al. Gabapentin for the treatment of Postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-1842

2. Associate Investigator, Intranasal Butorphanol for Treatment of Subarachnoid Opioid Induced Pruritus in the Parturient. 1997 - 1998

3. Primary Investigator, A seven week - Randomized, Double-Blind Placebo-Controlled, Parallel Group Study of Pregabalin in Patients with Chronic Low Back Pain. Protocol 1008-032 7/98-7/99

4. Primary Investigator: a five-week Double Blind, Placebo-Controlled, Parallel Group Study of Pregabalin (150 & 450 mg/day) in Patients with Postherpetic Neuralgia. Protocol 1008-30 7/98 – 7/99

5. Primary Investigator: Pregabalin Open-Label, Extension Safety Trial in Patients with Chronic Pain. Protocol 1008-033 7/98 – 4/2001

6. Primary Investigator: Pregabalin Open-Label Trial in Chronic Pain Patients Meeting Treatment-Refractory Criteria: Protocol 100*-****-****. 7/2001

7. Primary Investigator: Pregabalin Open-label, Extension Safety Trial in Patients with Chronic Pain: Protocol 100*-***-*** 4/2002

8. Primary Investigator: Multi-Center Study for Development of Chronic Pain Screening Tool: NRA9450004 5/2002

9.Primary Investigator: REN-1654 in post-herpetic neuralgia: a multi-center,

placebo-controlled, 3 week dose-finding study, with a 3-week active treatment extension. Phase II 10/2003

Research Support Continued:

10. Primary Investigator: A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of lamotrigine in subjects with neuropathic pain and inadequate pain relief with gabapentin, tricyclic antidepressants or non-narcotic analgesic. NPP30010 11/2003

11.Primary Investigator: Multi-Center Trial :Validation Study of a Neuropathic Pain Screening Tool: Protocol NRA9450010 12/2003

12. Primary Investigator: A double-blind, randomized, placebo-controlled, 16 week, multicenter trial evaluating the efficacy and safety of levetiracetam 500mg tablets in bid administration (daily dose ranging from 1000mg to 3000mg), in adults (> 18 years of age) suffering from postherpetic neuralgia. Protocol RPCE03K0605. 01/2004

13. Primary Investigator: A 5-week, Randomized, Double-blind, Placebo-controlled Multi-center Study of [S,S]-roboxetine in Patients with Postherpetic Neuralgia (PHN), Who are Gabapentin Treatment Failures. Phase II Protocol: A60610010 1/2004

14. Primary Investigator: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study of the Efficacy and Safety of Memantine In Comparison to Gabapentin in Patients with Postherpetic Neuralgia. Protocol MEM-MD-20 2004

15. Primary Investigator: A Multi-Center, Randomized, Double-Blind Placebo Controlled Study Assessing the Safety and Efficacy of XP009. in Postherpetic Neuralgia. 2004

16. Primary Investigator: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Pain due to Lumbosacral Radiculopathy: Protocol # REN-1654. 8/2004

17. Primary Investigator: Phase II, Open-Label, Follow-up Study to Evaluate Safety and Efficacy of Daily Dosing of REN-1654 for 27 weeks in Subjects with Post-Herpetic Neuralgia or Sciatica (Lumbosacral radiculopathy) Protocol # REN-1654-2-05

18. Primary Investigator: Phase II: A randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia, Neurogesx C116.

4/2005

19. Primary Investigator: Phase II, A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain. GSK # 767905/014 Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study Conducted Under In-House Blinding Conditions to Evaluate the Safety and Efficacy of Oral MK-0686 in the Treatment of Post Herpetic Neuralgia. 2006 – 2007

Research Support Continued:

20. Principal Investigator: An Open-Label Extension Trial Assessing the Safety and Tolerability of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia (PHN). 2006 – 2007

21. Principal Investigator: [S,S]-Reboxetine Dose-Range Finding Trial: A 16-Week, Randomized, Double-Blind, Placebo and Pregabalin Controlled, Multi-Center Trial of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia (PHN).2006 – 2008

22. Principal Investigator: [S,S]-Reboxetine Add-On Trial: A Randomized, Double-Blind, Placebo-controlled, Multi-center Trial of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia (PHN) Concomitantly Treated with Pregabalin 2007 – 2007

23. Principal Investigator: A Phase 2B Long-Term, Randomized, Open-Label, Safety and Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442G) with Routine Care in Patients with Chronic Painful Diabetic Peripheral Neuropathy (DPN).2007 – 2008

24. Principal investigator: A multicenter, Long-Term, Open Label Study of [S.S.] Reboxetine Administered Once Daily in Patients with Fibromyalgia. Protocol # A6061046. 9/2007-2008

25. Principal Investigator: Phase II Study of QR-333 for the Treatment of Symptomatic Diabetic Peripheral Neuropathy. 2007 – 2008

26. Principal Investigator: A Global, Multicenter, Randomized, Double Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects with Diabetic Neuropathic Pain.2007 – 2008

27. Principal Investigator: Pfizer Phase II B. Long-Term, Randomized, Open -Label, Safety and Tolerability Trial Comparing [S.S] Reboxetine (PNU-165442G) with Routine Care in Patients with Chronic Painful Diabetic Peripheral Neuropathy (DPN). 2007- 2008

28.Principal Investigator: Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof of Concept Study of the Analgesic Effects of RN 624 In Adult Patients with Postherpetic Neuralgia. VRX-RET-E22-NP201. 2007-2008

29. Principal Investigator: Pfizer Precision Protocol : A Randomized, Double-Blind, Parallel Group Study of Cardiovascular Safety and Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease comparing celecoxib with naproxen and ibuprofen. Protocol #A3191172

30. Principal Investigator: A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof of Concept Study of the Analgesic Effects of RN 624 In Adult Patients with Postherpetic Neuralgia. Pfizer: A4091005, 7/2008

Research Support Continued:

31 Principal Investigator: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Dose Ranging Exploration Study of Sativex In Relieving Pain in Patients with Advanced Cancer, Who Experienced Inadequate Analgesia During Optimized Chronic Opioid Therapy. GW Pharma, Protocol #GWCA 0701.2008-2009

32.Principal investigator: A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study of the Long-Term Analgesic Efficacy and Safety of Tanezumab Alone, or in Combination with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone in Patients with Osteoarthritis in the Knee or Hip. Pfizer Protocol #A4091025 2008 to present.

33.Principal Investigator : An Open Label Study of the Use of Topical Lidocaine (2.5%) / Prilocaine (2.5%) Cream as a Pre-Treatment for NGX-4010. In Subjects with Postherpetic Neuralgia (PHN). Neurogesix Protocol#:C123. 2009

34. Principal investigator: A multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate if the, safety, and tolerability of JNJ42160443 in subjects with postherpetic neuralgia and post-traumatic neuralgia, followed by a double-blind study extension and an open label safety extension. 2009

35. Principal Investigator: A 15 Week, Randomized, Double Blind, Parallel-Group Placebo-Controlled, Flexible-Dose, Safety and Efficacy Study of Pregabalin in Adolescents (12-16 Years Old) With Fibromyalgia; Protocol A0081180. 2011

36. A 6-Month, Open-Label, Safety Trial of Pregabalin in Adolescent Patients with Fibromyalgia; Protocol A0081231. 2011

37. A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects with Diabetic Neuropathic Pain; Protocol M11-891. 2011

38. A Phase IV, Prospective, Observational Trial Evaluating Xeomin (Incobotulinumtoxin A) for Cervical Dystonia or Blepharospasm in the United States; Protocol MRZ 60201-4066-5. 2011

Lecturer /Consultant:

Practical Pain Management. (Journal): Editorial Advisory Board :

Tennant FA Editor in Chief, Publisher, Vertical Health, LLC, Montclair NJ 2005-present.

Other consultant information and references are available upon request.

Contact this candidate